Skip to main content
Premium Trial:

Request an Annual Quote

Shifts at Pfizer

Pfizer is closing a research and development site in the UK at Sandwich, Kent, notes In the Pipeline's Derek Lowe. About 2,400 people work at the site and Pfizer says that it hopes to transfer a few those positions to other sites. "Although the company says that perhaps several hundred may find positions elsewhere, this is a major blow to drug discovery operations in the UK," Lowe says. The BBC adds that Pfizer manufacturing operations in Sandwich were shuttered in 2007.

The BBC also says that the closing is part of Pfizer's reorganization of its R&D operations and Ed Silverman at Pharmalot adds that, in the US, Pfizer is moving some of its R&D operations from Groton, Connecticut, to Cambridge, Massachusetts.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.